Does posttreatment prostate specific antigen nadir predict prostate cancer specific and all cause mortality?
Posttreatment prostate specific antigen nadir is significantly associated with the risk of prostate cancer specific and all cause mortality after radiation with or without androgen deprivation therapy. A suboptimal prostate specific antigen nadir may identify candidates for earlier intervention to prolong survival.
Complex coronary pathology as measured by the SYNTAX score did not affect the long-term outcome after CABG in this study.